Article

Cardiotoxicity from Bruton tyrosine kinase inhibitors (BTKi) – an analysis of an administrative health claims database

2024-02-14

Abstract excerpt

<h4>Background: </h4> First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of cardiotoxicity in clinical trials. <h4>Objective:</h4> Given paucity in real-world data on the overall cardiac risk factor profile, especially with the newer BTK...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b67b4414-ecbb-513f-937c-e21d8d36019b
DOI: 10.21203/rs.3.rs-3950083/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cardiotoxicity from Bruton tyrosine kinase inhibitors (BTKi) – an analysis of an administrative health claims databaseDOI 10.21203/rs.3.rs-3950083/v1Read

Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysisSemantic proximity Read

Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.Semantic proximity Read

Cardiotoxicity Associated with Targeted Therapies in Lung Cancer: A Retrospective Cohort Study of 2,427 Patients with FAERS Pharmacovigilance ValidationSemantic proximity Read

Kinome profiling allows examination and prediction of kinase inhibitor cardiotoxicitySemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy.Semantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?Semantic proximity Read

[Expert consensus on adverse events management of highly selective RET-TKIs (2026 edition)].Semantic proximity Read